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1.  Description of methods  
 
HIV Synthesis Transmission Model 
The HIV Synthesis transmission model is an individual-based stochastic model of heterosexual 
transmission, progression and treatment of HIV infection within a southern African context (1-3).  Full 
updated model details are in the supplementary material for ref 3, but a brief description follows.    All 
variables are updated in 3 month periods in the model, which includes an age- and gender- structure.  
Sexual risk behaviour is modelled as the number of condomless-sex short term partners and presence of 
a condomless-sex long-term partner in each period. In any given period, the probability of an 
uninfected person having a condomless-sex partner who is infected with HIV depends on their number 
of partners and on the prevalence of HIV amongst partnerships formed by those of the opposite gender, 
accounting for patterns of age mixing.  Given exposure to an infected partner, the probability of 
transmission depends on the viral load level of the partner (obtained by sampling from the distribution 
of viral load levels in partnerships formed by HIV infected people, accounting for gender and age), on 
the estimated risk of transmission at that viral load, presence of a concurrent sexually transmitted 
infection and on gender.  Emergence of resistance on ART is dependent on adherence and the current 
number of active drugs.  Adherence is assumed to have several components, with a distribution across 
individuals of a life long tendency, and also in the extent of period to period variation.  In addition, 
various factors can influence adherence, including the initial measurement of viral load > 1000 
copies/mL which is assumed to lead to an increase in adherence (with new adherence level sampled 
from a Normal distribution with mean 90% and standard deviation 5%, and a 10 fold increase in the 
rate of restarting ART in those who have interrupted) in 70% of people as a result of targeted adherence 
intervention; this is consistent with data showing that a high proportion of people with measured viral 
load > 1000 copies/mL subsequently achieve viral suppression without a change in ART (4-6).  The 
appropriate duration to assume for this effect is uncertain and the impact of adherence interventions has 
often been shown to diminish with time (7).  We assume that the adherence intervention is potentially 
effective only the first time it is performed and that for 40% the effect is permanent (28% of those with 
a viral load >1000 copies/mL), but that in the remaining 60% (42% of those with viral load>1000 
copies/mL) it lasts only 6 months (except we assume the effect on restarting ART is permanent).   We 
also model the possibility that in some individuals at certain times the adherence is so low that the 
individual has in fact interrupted ART, although this is undeclared to the clinic so the person is still 
considered by the clinic in any records kept as being on ART.   Such a lack of adherence is thought to 
explain why some people have no resistance mutations present at virologic failure (8-10), and we 
mimic this in our model.  Regarding resistance and transmission, the presence or not of resistance 
mutations does not influence the risk of transmission (i.e. virus with resistance mutations present is 
assumed equally transmissible as virus without such mutations, for a given viral load).  For people who 
have become infected with HIV the variables modelled include viral load, CD4 cell count, presence of 
resistance mutations, risk of AIDS and death.  Resistance is modelled in terms of the presence or not of 
specific mutations (e.g. number of thymidine analogue mutations (TAMS); presence of M184V (yes or 
no; y/n), K65R (y/n); L74V (y/n); Q151M (y/n), presence of a key NNRTI mutation (y/n); major PI 
mutations (y/n).  Distinction is made for each mutation as to whether it is only present in minority virus 
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(if the patient has a mutation present but has stopped drugs that select for that mutation), so assumed 
not transmissible, or if it is present in majority virus, and hence assumed transmissible.  For a newly 
infected person, the probability of being infected by a person with resistant virus as their majority virus 
population is determined by the probability, for the given viral load level of the person from whom the 
virus has been acquired, that drug resistance mutations are present in the concurrent infected 
population, again taking into account gender, age and number of partnerships formed.  It is not assumed 
that all resistance mutations present in majority virus of the source partner are established as a mutation 
in virus in the newly infected person.  This is dependent on the specific mutation.  If a mutation is 
transmitted and established in the new host it is assumed to persist in majority virus but with a certain 
probability of loss of persistence in majority over time (11), but thereafter it remains in minority virus  
and is selected back as majority virus if relevant ART is initiated.  We also consider the possibility of a 
person who is already infected become super-infected, including with drug resistant HIV (12).   
NNRTI-resistance acquired through use of nevirapine as PMTCT is assumed to eventually disappear 
even from minority virus. 
 
The model structure used aims to capture the essence of the underlying biological mechanisms by 
which resistance and virologic failure arise, and is the result of careful consideration in discussion with 
virologists, clinicians and other modellers.   The use of this structure means that few of the parameter 
values come directly from specific published values as estimates of the parameters relevant to our 
model structure are mostly not available.   We have generated in the supplementary material to ref 3 a 
range of model outputs for comparison with published estimates to assess model calibration. 
 
Programmatic scenarios modelled 
In order to generate programmatic scenario scenarios with various levels of on-going TDR at t0 – the 
time point at which the policy decision is being made (which was arbitrarily chosen as the year 2017) 
we varied many of the parameters that most strongly determine the level of TDR present in a 
population in 5000 model runs.  These were: the adherence profile, the extent to which resistance 
mutations are transmitted (res_trans_factor; see model details),  the rate with which transmitted 
mutations disappear from majority virus and become present only in minority virus 
(rate_loss_persistence), the underlying rate of interruption of  ART (the actual rate at any point depends 
also on the average adherence (adhav) and presence of toxicity as well as this underlying rate; see 
model details), the probability of the drug supply being interrupted, and the rate of generation of new 
NNRTI drug resistance mutations as a result of interruption (due to the long tail in drug level).  
Distributions assumed for these are shown below under Parameters and Distributions.    In order to 
generate programmatic scenarios with a high level of TDR we used a distribution of adherence patterns 
which includes a relatively high number of programmatic scenarios for which a high proportion of 
people have poor adherence.   In such programmatic scenarios the proportion of people on ART with 
VL suppressed is low and the death rate of those on ART high.  Although there are relatively few data, 
the proportion of programmatic scenarios in sub Saharan Africa with these characteristics is probably 
lower than it is in our programmatic scenarios, but we wished to include a high proportion of 
programmatic scenarios in which levels of NNRTI TDR are high in order to study the effects of 
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potential new policies in this context.   For all programmatic scenarios, we assume that ART (first line 
regimen consisting of stavudine, 3TC and nevirapine before mid-2010 and tenofovir, 3TC and 
nevirapine after mid-2010) is provided with use of CD4 cell count monitoring to decide on when to 
start ART (CD4 cell count 200 /mm3 from 2003; CD4 cell count 350 /mm3 from 2010, 500 cells /mm3 
from 2017).  We assume that up to t0 the CD4 cell count is used to monitor people on first line to 
determine eligibility for switch to second line (CD4 cell count < 100 cells/mm3, as in the DART trial 
(13)).  In both cases we assume only a 3% chance of switch in each 3 month period after the criteria is 
fulfilled, to reflect the very low rates of switching seen in practice.  Then at t0 for each of these 
programmatic scenarios we considered what would be the predicted outcomes over the following 15 
years (i.e. to 2032) of potential policy options, according to the current level of NNRTI-resistance in 
people about to start ART, excluding women with previous antiretroviral therapy for PMTCT.  The 
potential policies are as follows (i)  current policy, (ii) change of the standard NNRTI-based regimen to 
a bPI-based first line regimen (with a second line involving continued use of a bPI (bPI) and 
replacement of the tenofovir with zidovudine), (iii) individual-level resistance testing prior to ART 
initiation to detect key NNRTI mutations to inform whether to use an NNRTI-based or PI-based 
regimen as first line, (iv) introduction of routine (6m, 12m and then annual) viral load monitoring, 
replacing CD4 cell count monitoring (so unlike in the first three policies, in which the above-described 
CD4 count monitoring is assumed to continue, the first failure criteria is two consecutive viral load 
values > 1000 copies/mL) , or (v) measurement of viral load at 6 months after start of ART, with a 
repeat test at 1 year if the value is > 1000 copies/mL , and with first line failure being called  if the level 
at one year is above 1000 cps/mL, but otherwise not replacing CD4 cell count monitoring.  We assume 
that the rate of switching after failure criteria have been fulfilled is increased to 0.2 per 3 months after 
t0.    These potential policies were formulated at a WHO working group meeting in 2012.  We 
undertook 5000 model runs as a balance between having sufficient stability of estimates and feasibility 
of running very large numbers of simulations.  In order to most clearly understand their impact we 
assume that policies are fully implemented immediately.   The model was programmed in SAS 9.3. 
 
Economic Analysis  
All of the evaluated alternatives have different cost implications and the ability of health care systems 
to fund interventions differs widely.  The health benefits associated with the alternative policies were 
estimated on the basis on quality adjusted life years (QALYs) lived.  Costs were estimated based upon 
resource use in the delivery of the policies (e.g. number of viral load tests provided, first line drug 
regimen used) and associated unit costs (see below).  The time horizon for the analyses is 2017-32, and 
both costs and health benefits are discounted to present value using a 3.5% per annum discount rate. 
 
The expected costs and health outcomes (QALYs) associated with each of the policy alternatives can be 
compared to inform which is likely to represent best value from available resources.  The results are 
presented in the form of a ranking of the net monetary benefit across all policy options .  The net 
monetary benefit (NMB) is expressed as the QALYs associated with a policy, multiplied by a cost-
effectiveness-threshold, less the costs of that policy.  The cost-effectiveness-threshold represents the 
opportunity costs of resources required to fund the intervention, in terms of the health gains those 
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resources could generate if used for alternative purposes (14).  Based on current evidence, the policy 
that generates the highest NMB should be adopted and can be expected to maximize health gains in the 
population (15,16).  We provide results for a range of cost-effectiveness-thresholds.  For the more 
poorly resourced health systems in sub Saharan a value of $500 or even lower is probably realistic 
given that many interventions offering health gains at this amount or less remain unfunded.   
 
We assume the objective is to maximize health.  Policies are made subject to uncertainty and on the 
basis of best current evidence.  In reality, policy-makers may have the option to undertake more 
research to guide policy (for instance to better understand the effectiveness of the interventions, or to 
obtain better estimates of TDR in the population).  Furthermore, we assume that there are no costs 
incurred with the change in strategy beyond those included as depreciation costs in the unit cost 
estimates.  If there are other irrecoverable costs to adopting new policies we assume that the 
interventions will be used for their full effective lifetimes.  This could be important because the 
introduction of laboratory-based viral load monitoring and resistance testing, in particular, would 
require significant capital investment that may not be necessary if point of care alternatives become 
available in the near future. 
 
We performed sensitivity analyses in which we changed the cost of viral load from the $45 in the base 
scenario to $15, in which we also changed the cost of resistance testing from $250  to $100  and in 
which we reduced the cost of the bPI by 50%.   Also we considered a smaller effect of viral load 
measurement on adherence. 
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2.  Supplementary tables and figures 
 
Supplementary Table 1: Difference in discounted costs and QALYs over 15 years compared with 
no change in policy according to t0 level of NNRTI-resistance in ART initiators and new policy 
option.  Mean over 5000 programmatic scenarios.   
 
 
---------------------------------------------------------------------------------------------------------------------------------------------------- 
  New policy option starting from t0 
 
Level of  bPI first line Pre-ART   Viral load  Viral load  
NNRTI    regimen
+
  resistance   monitoring test at 6 
resistance at   testing
++
  
+++
  months  
start of ART                  after ART 
at t0        initiation 
        
++++ 
------------------------------------------------------------------------------------------------------------------------------------------------------ 
Difference in discounted cost in 2013 $ (over 15 years; mean over programmatic scenarios) compared with current policy 
Difference in discounted QALYs (mean over programmatic scenarios) compared with current policy 
  
< 5%  2,456,000  826,000  1,086,000  187,000   
  491  233  327  128  
   
5%-10%  2,576,000  977,000  1,161,000  224,000   
  729  331  454  175  
            
10%-15%  2,534,000  1137,000  1,192,000  306,000   
  1171  490  740  366 
            
15%-20%  2,443,000  1,280,000  1,221,000  441,000   
  1752  728  1174  674 
 
20%-25%  2,521,000  1,458,000  1,297,000  555,000   
  2192  861  1505  867 
 
25%-  2,691,000  1,626,000  1,390,000  596,000   
  2505  1070  1746  893 
------------------------------------------------------------------------------------------------------------------------------------------------------ 
 
NNRTI = non-nucleoside reverse transcriptase; bPI = boosted protease inhibitor 
+ change of the standard NNRTI-based regimen to a bPI-based first-line regimen 
++ individual-level resistance testing prior to ART initiation to detect key NNRTI mutations to inform 
whether use of an NNRTI-based or bPI-based regimen is optimal as first-line treatment,  
+++  introduction of routine (6m, 12m and then annual) viral load monitoring, replacing 6 monthly 
CD4 cell count monitoring 
++++  a single routine measurement of viral load at 6 months after start of ART, with routine CD4 
cell count monitoring. In this last scenario, if the viral load is > 1000 copies/mL, it is repeated 6 
months later and if above 1000 copies/mL, a switch to second-line is effected.   
It should be noted that these are mean across all programmatic scenarios in each stratum of t0 level of 
NNRTI resistance at start of ART.  Calculation of the net monetary benefit based on these means is a 
different approach to that used in Figure 2 of the main manuscript, where the policy with the highest 
net monetary benefit was calculated for each programmatic scenario and then the one that was most 
frequently the highest was declared to be the most cost-effective. 
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Supplementary Table 2: Median (90% range) % with adherence > 80% according to level of 
NNRTI-resistance at start of ART in 2017 (t0).    
   
Level of NNRTI-resistance at start of ART in 2017 
 
<5%  5%-  10%-  15%-  20%-  25%- 
------------------------------------------------------------------------------------------------------------------------------------------------------- 
87%  84%  77%  60%  54%  54% 
(78%-91%) (72% - 90%) (55% - 86%) (42% - 81%) (39% - 67%) (38% - 65%) 
------------------------------------------------------------------------------------------------------------------------------------------------------ 
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3. Parameter values and distributions    
 
Details of variables are explained in Model details in Supplement to Ref 3. 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Sexual behaviour 
 
Sexual behaviour model structure:  base structure (rbm=4) 
 
Change in propensity to have a long term condomless sex partner after HIV diagnosis (ch_risk_diag): 9/13   
 
Change in propensity to have short term (“new”) condomless sex partners after HIV diagnosis (ch_risk_diag_newp):  5/6 
 
Date at which population level change in condomless sex behaviour occurs (date_ch_risk_beh): 1995      
 
Change in propensity to have condomless sex (“risk behaviour”) with short term partners after threshold for population 
level change in condomless sex behaviour reached (ch_risk_beh_newp): Beta(50,70)   
 
Change in propensity to have a long term condomless sex (“risk behaviour”) with short term partners after threshold for 
population level change in condomless sex behaviour reached (ch_risk_beh_ep): Beta(60,60) 
 
Rate of starting new long term condomless sex partnership in 15-25 year age group (eprate): 0.1 
 
Poisson mean for moderately high short term partner group (see model details) (highsa): 4.5    
 
Poisson mean for highest short term partner group (see model details) (swn):7    
 
Factor to change overall average level of condomless sex with short term partners (newp_factor): 5.5  
 
Proportion of the population who have a lifetime reduced number of condomless sex partners (see model details) 
(p_rred_p): 0.20 
 
Probability per 3 months of pregnency at age 35-45 (prob_pregnancy_base): 0.037  
Fold difference in pregnancy rate at age: 1525: 1.04; 25-35: 1.03; 45-55: 0.975 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Transmission  
 
Fold difference in transmission rate for a given viral load (see Model details for base assumption on transmission rate by 
viral load2): 1.0 
 
Rate of transmission in primary HIV infection (lasting 3 months) (tr_rate_primary): 0.25 
 
Transmission rate when plasma viral load is < 500 cps/mL (tr_rate_undetec_vl):  0.001 
 
Fold higher rate of transmission from women to men, compared with men to wormen (fold_change_w):   1.5 
 
Fold higher rate of transmission in young women compared with older women (fold_change_yw):  2.0 
 
Fold higher rate of transmission if current STI present (fold_change_sti):  3.0 
 
Fold lower transmission rate for short term partners compared with long term (reflecting average lower number of sex 
acts) (fold_tr_newp):  5/14 
 
Super-infection: for people with HIV super-infected with a  resistant virus, we assume a low (20%) probability that these 
mutations are established as resistance mutations. 
 
Adjustment to factor determining extent to which some transmitted resistance is effectively immediately lost (even from 
minority virus) (res_trans_factor):  lognormal(ln 0.8 ,0.20)    
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Probability per 3 months of loss of persistence of transmitetd mutations from majority virus to minority virus (same for 
each mutation) (rate_loss_persistence):  lognormal( ln 0.02,0.30)   
 
Probability per 3 months of loss of NNRTI mutations, acquired due to PMTCT, from majority virus to become only in 
minority virus (rate_loss_nnres_pmtct_maj):  0.25 
 
Probability per 3 months of loss of virus with NNRTI mutations acquired due to PMTCT, from minority virus to 
effectively be extinct altogether (rate_loss_nnres_pmtct_min):  0.25 
 
Prevalence of male circumcision: 0.1 
 
Date of introduction of VMMC: 2008 
 
Rate of increase in probability of VM male circumcision per 3 months: (circ_inc_rate):  lognormal( ln 0.003, 0.5)  
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
 
HIV testing  
 
Date start of testing (date_start_testing): 1996 
 
Initial test probability for those with WHO condition (this increases by 0.008  per 3 mths after testing is introduced, up to 
2015) (test_rate_who4): 0.2  
 
Initial test probability for those with TB (this increases by 0.005  per 3 mths after testing is introduced, up to 2015) 
(test_rate_tb): 0.1 
 
Initial test probability for those with current WHO 3 condition (this increases by 0.0012  per 3 mths after testing is 
introduced, up to 2015) (test_rate_who3): 0.03 
 
Reduction in rate of testing if never had condomless sex (red_test_neversex): 0.33 
 
Annual linear increase in testing (an_lin_incr_test): 0.000625 x 0.0025  
Date start testing ANC (date_start_testanc): 1994 
 
Rate test ANC (rate_testanc_inc): =0.0025 
 
Fold difference in ANC testing rate by age: 
fold_probanc_1519=0.73, fold_probanc_2024=1x1.36,fold_probanc_2529=0.9x1.14, fold_probanc_3039=0.8x1.00, 
fold_probanc_4049=0.70, fold_probanc_ov50=0.56 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Natural progression  
 
Probability of being lost (unlinked to care) at diagnosis (prob_loss_at_diag): 0.6 
 
Initial CD4 count at infection (square root scale) (mean_sqrtcd4_inf): 27.5 
 
Factor adjusting basic rate of natural cd4 decline  (see model details) (fx):  1.0 
 
Factor adjusting basic rate of natural viral load change  (see model details) (gx):  1.0 
 
Fold increase in risk of WHO 3 condition, compared with risk of WHO 4 condition, for given level of CD4 count, viral 
load and age (fold_incr_who3):  5 
 
Fold decrease in risk of HIV-related death, compared with risk of WHO 4 condition, for given level of CD4 count, viral 
load and age (fold_decr_hivdeath): 0.25 
 
Fold difference in risk of WHO 4 condition, for given level of CD4 count, viral load and age, compared with base 
assumption (see model details) (fold_change_in_risk_base_rate): 1.0 
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Increase in death rate in 3 months period in which a WHO 4 condition is present (incr_death_rate_adc):   5 
 
Increase in death rate in 3 months period in which TB is present incr_death_rate_tb): 2   
 
Fold difference in non HIV related mortality, compared with base assumption (fold_change_ac_death_rate):  1 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
HIV monitoring, loss, return, interruption of art and restarting  
 
Risk of loss to follow-up per 3 mths among those not on ART (rate_lost): 0.05 
 
Probability of simultaneously being lost to follow-up amongst those stopping ART (prob_lost_art): 3/11 
 
Probability (per 3 mths) of return to care for person lost (if no WHO 4 condition present – value is 1 if present) 
(rate_return): 0.05 
 
Basic probability of restart of ART in those remaining under care who have stopped/interrupted ART (this is also 
influenced by presence of WHO 3 or 4 conditions) (rate_restart):  0.2 
 
Probability of ART initiation per 3 months after eligibility fulfilled, if visting clinic: 0.5 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
ART   
 
ART introduction date: 2003 
 
Probability of switching to second line treatment, given first line failure (by whatever definition is being used) 
(pr_switch_line): 0.03 (changes to 0.2 after t0, 2017) 
 
Pattern of adherence*: 1 20%, 2 20%, 3 20%, 4 20%, 5 20%.  
 
Reduction in adherence resulting from presence of TB or a WHO 4 condition (red_adh_tb_adc):  0.1 
 
Average reduction in adherence resuting from current toxicity (the actual reduction varies by inidvidual person) 
(red_adh_tox_pop):  0.05 
 
Additional "effective" adherence for people on NNRTI regimens due to longer half life (add_eff_adh_nnrti):  0.1 
 
Average change in adherence on second line (degree of change varies by indvidual – note this can be a positive or negative 
change) (altered_adh_sec_line_pop) = 0.05 
 
Proportion of people for whom a measured viral load > 1000 leads to an improvement in adherence (for the first time such 
a measurement is made only) (adh_effect_of_meas_alert): 0.7 
 
Extent to which the CD4 change is more favourable on a virologically failing BPI-regimen compared with an NNRTI-
regimen (poorer_cd4_rise_on_failing_nnrti): -6  
 
Standard deviation for intra-subject variation in CD4 count (sd_cd4): 1.2  
 
Standard deviation for the measurement error in CD4 count (sd_measured_cd4):  1.7 
 
Base probability of interrupting ART per 3 mths (actual probability also depends on time on continuous ART, presence of 
current toxicity and average adherence – see model details) (rate_int_choice):  lognormal( ln0.03,  0.30)  
 
Probability of drug stock out, and hence ART initerrupted (prob_supply_interrupted):  lognormal( ln0.02, 0.30)   
 
Probability that drug supply resumed during stock-out (prob_supply_resumed):  0.8 
 
Probability of NNRTI-resistance emerging in women taking SD nevirapine for PMTCT: 0.35 
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Probability of NNRTI-resistance emerging in women taking nevirapine plus at least one other antiretroviral for PMTCT: 
0.045 
 
Fold difference in risk of mutations arising, for given number of active drugs, viral load and current adherence  level, 
compared with base risk (see model details) (fold_change_mut_risk): 1 
 
Similarly, specifically for thymidine analogue mutations: (fold_change_tams_risk): 1 
 
Similarly, specifically for Q151M cross nucleoside resistance mutation: (fold_change_151_risk): 1 
   
Standard deviation representing inter-patient variation in rate of CD4 rise - when CD4 is rising (sd_patient_cd4_rise_art): 
0.2  
 
Risk of NNRTI-resistance emergence due to stopping an NNRTI regimen (due to the tail in presence of drug meaning 
effective monotherapy): 0.03 
 
Fraction of people who stop ART (and are still visiting the clinic) for whom the clinic is not aware of the interruption and 
is hence treating the patient as if they were on ART (and hence may switch to the next line having wrongly classified them 
as virologically failing): (clinic_not_aw_int_frac): 0.6 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
* There are various adherence pattern distributions (numbered 1-5) considered.  adhav is an individual’s average level of 
adherence and adhvar describes their period to period variability  
 
Adherence pattern 1 (3% probability adhav   =  0.50 adhvar  =  0.2, 3% probability adhav   =  0.80 adhvar  =  0.2, 14% 
probability adhav   =  0.90  adhvar  =  0.06 , 80% probability  adhav   =  0.95  adhvar =  0.05).     
 
Adherence pattern 2 (5% probability  adhav   =  0.50  adhvar  =  0.2, 10% probability adhav   =  0.80 adhvar  =  0.2, 27% 
probability adhav   =  0.90 adhvar  =  0.06, 38% probability adhav   =  0.90  adhvar =  0.05, 20% probability  adhav   
=  0.95 adhvar =  0.05) 
 
Adherence pattern 3 (15% probability adhav   =  0.50 adhvar  =  0.2, 15% probability adhav   =  0.70 adhvar  =  0.2,    
50% probability adhav   =  0.90 adhvar  =  0.06, 20% probability  adhav   =  0.95 adhvar =  0.05)     
 
Adherence pattern 4 (30% probability adhav   =  0.50 adhvar  =  0.2, 30% probability adhav   =  0.70 adhvar  =  0.2, 10% 
probability adhav   =  0.90  adhvar  =  0.06, 30% probability adhav   =  0.95 adhvar =  0.05)     
 
Adherence pattern 5 (30% probability adhav   =  0.50  adhvar  =  0.2, 30% probability adhav   =  0.60  adhvar  =  0.2,    
10% probability  adhav   =  0.70 adhvar  =  0.06, 30% probability  adhav   =  0.90 adhvar =  0.05)     
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Costs     
 
All costs are in $1000 per 3 month period in 2013. 
 
-------------------------------------------------------------------------------------------------------------------------------------------------- 
 
Drug costs* below increased by 20%** for supply chain etc (as in b) – costs are annual unless stated  
 
zidovudine: 0.070        
tenofovir: 0.048        
ddI: 0.100        
lamivudine: 0.021         
stavudine: 0.024         
nevirapine: 0.028         
efavirenz: 0.039         
lopinavir/r: 0.268         
atazanavir/r: 0.219  
 
Mean cost of treatment of a WHO 4 condition over 3 months (cost is incurred for 3 months): 0.200+       
Mean cost of treatment of a WHO 3 condition over 3 months (cost is incurred for 3 months): 0.020+         
Mean cost of treatment of TB per 3 months (cost is incurred for 6 months): 0.050+         
 
Cotrimoxazole annual cost: 0.005 +          
CD4 count measurement: 0.010 *** +      
Viral load measurement: 0.045 ***  +     
Clinic visit cost: 0.020 +       
Resistance test cost: 0.250 +++        
HIV test (including personnel costs):  0.010 **       
 
-------------------------------------------------------------------------------------------------------------------------------------------------- 
 
* Untangling the web of antiretroviral price reductions.  16th Edition – July 2013.  www.msfaccess.org.  (17) 
** Eaton J et al.  How should HIV programmes respond to evidence for the benefits of earlier treatment initiation ? A 
combined analysis of 12 mathematical models.  Lancet Global Health 2013. (18) 
***Keebler D, Revill P, et al.  How Should HIV Programmes Monitor Adults on ART? A Combined Analysis of Three 
Mathematical Models.  Lancet Global Health 2013.  (19) 
+ Specific data not available on average unit costs of treating WHO stage 3 and 4 conditions and per clinic visit costs - 
costs used are informed by evidence synthesis from studies that cost according to current CD4 count of those in pre-ART 
care, cost of ART initiation, which also include costs of CD4 tests ( 18.)    
+++  estimate of potential lowest feasible cost with centralised testing. 
 
 
Utilities*   
 
Values are 1 except for the following: 
Any drug toxicity in current 3 month period: 0.95 
Any WHO 3 condition (except TB) in current 3 month period: 0.78 
Current TB in current 3 month period: 0.60 
Any WHO 4 condition in current 3 month period: 0.46 
 
* Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability 
weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129–43.  (20) 
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